FIELD: medical biotechnology.
SUBSTANCE: invention relates to medical biotechnology. The method is based on measuring the level of MMP-9 mRNA in the blood plasma relative to the representation of the reference RNA. The obtained indicators are used to calculate the ratio of expression levels for each specific sample. The value of the obtained indicator is interpreted as a marker of early tumor formation in the mammary gland and ovaries. The invention can be used to detect early stages of breast cancer and ovarian cancer.
EFFECT: method provides a highly sensitive and objective quantitative characterization of the level of mRNA expression of MMP-9, which allows early minimally invasive diagnosis of breast and ovarian cancer.
1 cl, 2 tbl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DIAGNOSING BREAST CANCER BY LEVEL OF EXPRESSION OF IL-10 AND/OR IL-17 MRNA IN BLOOD PLASMA | 2020 |
|
RU2752971C1 |
| METHOD FOR DIAGNOSING BREAST CANCER BY LEVEL OF MRNA TGEβ AND TNFα IN BLOOD PLASMA | 2019 |
|
RU2742209C1 |
| SET OF REAGENTS FOR DETERMINING THE RISK OF RECURRENCE OF BREAST CANCER | 2017 |
|
RU2671557C1 |
| METHOD OF PREDICTING RISK OF DEVELOPING TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2811257C1 |
| METHOD FOR PREDICTION OF BREAST CANCER RISK DEVELOPMENT IN OBESE WOMEN | 2022 |
|
RU2795244C1 |
| METHOD FOR PREDICTION OF BREAST CANCER RISK DEVELOPMENT IN NON-OBESE WOMEN | 2023 |
|
RU2795726C1 |
| DIAGNOSTIC TECHNIQUE FOR BREAST CANCER BY BLOOD PLASMA INTERLEUKIN IL-8 AND/OR IL-18 RNA LEVEL | 2010 |
|
RU2451937C2 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPING BREAST CANCER IN WOMEN USING MOLECULAR GENETIC DATA | 2022 |
|
RU2795897C1 |
| DIAGNOSTIC TECHNIQUE FOR BREAST CANCER AND OVARIAN CANCER | 2017 |
|
RU2696114C2 |
| METHOD FOR PREDICTING DEVELOPMENT OF METASTASES IN PATIENTS WITH BREAST CANCER | 2018 |
|
RU2675236C1 |
